SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.141
NA - Nord America 2.717
EU - Europa 1.027
SA - Sud America 585
AF - Africa 71
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.544
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.565
SG - Singapore 1.231
BR - Brasile 436
CN - Cina 431
VN - Vietnam 401
IT - Italia 374
HK - Hong Kong 364
BD - Bangladesh 268
DE - Germania 118
FR - Francia 99
JP - Giappone 99
ID - Indonesia 97
GB - Regno Unito 96
RU - Federazione Russa 92
IN - India 82
FI - Finlandia 77
MX - Messico 70
AR - Argentina 59
CA - Canada 57
NL - Olanda 33
ZA - Sudafrica 32
UA - Ucraina 28
IQ - Iraq 25
TR - Turchia 25
PL - Polonia 23
EC - Ecuador 21
AT - Austria 18
PH - Filippine 16
VE - Venezuela 16
CO - Colombia 14
ES - Italia 13
SA - Arabia Saudita 13
KR - Corea 10
MY - Malesia 10
PK - Pakistan 10
PY - Paraguay 10
SE - Svezia 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
JO - Giordania 8
LT - Lituania 8
MA - Marocco 8
BO - Bolivia 7
UY - Uruguay 7
CH - Svizzera 6
UZ - Uzbekistan 6
DZ - Algeria 5
EG - Egitto 5
HN - Honduras 5
CR - Costa Rica 4
KE - Kenya 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
TN - Tunisia 4
AL - Albania 3
BE - Belgio 3
BG - Bulgaria 3
BY - Bielorussia 3
PS - Palestinian Territory 3
RS - Serbia 3
SV - El Salvador 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GT - Guatemala 2
IL - Israele 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MK - Macedonia 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GN - Guinea 1
GR - Grecia 1
GY - Guiana 1
IE - Irlanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 7.529
Salva come PNG Salva come JPEG
Città #
Singapore 673
Ashburn 498
Santa Clara 440
San Jose 408
Hong Kong 362
Ho Chi Minh City 146
Hanoi 103
Tokyo 95
Beijing 94
Council Bluffs 86
New York 81
Jakarta 74
Lauterbourg 73
Los Angeles 63
Helsinki 61
Mexico City 49
Chicago 41
Chandler 40
São Paulo 40
Dallas 39
Bologna 32
Milan 31
London 30
Buffalo 27
Nuremberg 25
Orem 21
Rome 21
Munich 19
Da Nang 18
Ferrara di Monte Baldo 18
Hefei 18
Salt Lake City 18
Warsaw 18
Falkenstein 17
Haiphong 17
Shanghai 16
Montreal 15
Phoenix 15
Hải Dương 14
Johannesburg 14
Brasília 13
Denver 13
Florence 13
New Delhi 13
Baghdad 12
Brooklyn 12
Rio de Janeiro 12
Toronto 12
Biên Hòa 11
Lappeenranta 11
Moscow 11
San Francisco 11
Atlanta 10
Chennai 10
Elk Grove Village 10
Frankfurt am Main 10
Stockholm 10
Dhaka 9
Ferrara 9
Naples 9
Quito 9
Vienna 9
Amman 8
Düsseldorf 8
Guangzhou 8
Guayaquil 8
Paris 8
Seattle 8
Amsterdam 7
Belo Horizonte 7
Boston 7
Houston 7
Montevideo 7
Santiago 7
Ankara 6
Assago 6
Asunción 6
Buenos Aires 6
Bến Tre 6
Charlotte 6
Curitiba 6
Fortaleza 6
Hounslow 6
Kuala Lumpur 6
Manchester 6
Poplar 6
Yongsan-gu 6
Can Tho 5
Columbus 5
Guarulhos 5
Hangzhou 5
Jeddah 5
Juiz de Fora 5
Manaus 5
Mumbai 5
Princeton 5
Recife 5
Shenzhen 5
Sterling 5
São Gonçalo 5
Totale 4.342
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 176
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 167
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 148
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 147
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 140
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 138
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 128
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 126
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 122
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 120
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 118
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 115
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 113
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 104
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 101
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 101
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 98
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD 97
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 97
Challenges in lung cancer therapy during the COVID-19 pandemic 96
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 94
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 93
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 93
Biomarkers for immune checkpoint inhibitors--authors' reply 93
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 93
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 92
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 88
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 88
The emerging role of cancer nanotechnology in the panorama of sarcoma 87
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 86
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 86
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 85
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 84
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 82
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 82
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 81
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 79
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 79
COVID and Lung Cancer 79
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 78
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 77
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 77
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 72
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 72
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 71
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera 71
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 69
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 68
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies] 67
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 67
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 65
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 65
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 65
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 65
The future of mesothelioma treatment: time to shift gear 65
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 63
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 63
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 63
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 63
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report 61
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 61
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 61
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 59
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 59
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 58
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells 58
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 58
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 58
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 58
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 57
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 56
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 55
Levels of solubile angiogenin in chronic myeloid malignancies: clinical implications 55
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 55
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 54
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 52
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 52
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 52
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy 51
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 51
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 51
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 51
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 50
Epigenetic immunomodulation of hematopoietic malignancies 50
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 48
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 48
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 47
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma 47
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma 47
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies 45
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 45
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 43
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study 40
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 38
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial 38
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 37
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 34
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 32
Immunotherapy of brain metastases: breaking a “dogma” 28
Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT) 27
Totale 7.489
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.847
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 318
Totale 58.165
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024260 10 47 21 13 19 4 4 15 9 13 20 85
2024/20251.877 81 125 172 29 237 234 67 53 198 398 173 110
2025/20265.319 370 206 484 614 672 184 563 309 499 625 501 292
Totale 7.658